FDA approves Ready-to-Use Ephedrine Injection, Emerphed™

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

DATE OF RELEASE: April 21. 2020

Lincolnshire, Ill. — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial. With no need for compounding, diluting, or mixing, Emerphed saves valuable staff time while also reducing the potential for preparation error and waste.

“With the approval of our Emerphed Injection, Nexus Pharmaceuticals is looking to streamline the standard of care in the operating room,” said Mariam S. Darsot, Chief Executive Officer & President of Nexus Pharmaceuticals.

Shahid Ahmed, Chief Scientific Officer added, “By offering a premixed, ready-to-use formulation of ephedrine, we are helping to reduce precious time spent preparing drugs in the OR, as well as reducing waste and minimizing the potential for human error.”

Emerphed will be available in a ready-to-use 10 mL vial that does not require further dilution. Each vial contains 50 mg ephedrine sulfate in 0.9% sodium chloride.

About Emerphed

INDICATIONS AND USAGE

Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

WARNINGS AND PRECAUTIONS

Emerphed can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.

CONTRAINDICATIONS

None

OVERDOSAGE

Overdose of Emerphed can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and tachycardia. To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For full prescribing information, please see the following link.

About Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus Pharmaceuticals ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable, lifesaving treatment options when and where they’re needed most.

Media Contact

Diana Lebiecki
847-996-3790
dlebiecki@nexuspharma.net

Medika Life

Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Recent Posts

Ukraine: Worn Hearts, Steeled Resolve

I have traveled to Ukraine nearly 20 times. Each visit deepens my respect for how…

4 days ago

Medicaid at a Crossroads: Safe AI, Shifting Policy and the Stakes for People’s Health

Medicaid is one of America’s most complex and essential Federal health programs, serving more than…

2 weeks ago

Global childhood vaccination remains resilient, but equity cracks are widening

In 2024, immunisation data from WHO and UNICEF show that while 115 million infants (89%) received at…

3 weeks ago

Restrictive practices in medicine are holding high-income countries back

A paper in this week’s New England Journal of Medicine (NEJM) is part of a…

3 weeks ago

The Trauma of Witnessing Charlie Kirk’s Murder and PTSD

The psychological effects of public space shootings extend beyond physical harm because they create a…

3 weeks ago

Guns, Race, and Profit: The Pain of America’s Other Epidemic

BOGALUSA, La. — Less than a mile from a century-old mill that sustained generations in…

1 month ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More